此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems (Hybrid CATT1)

2026年11月6日 更新者:vTv Therapeutics

Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study

TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.

研究概览

详细说明

TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Modesto、California、美国、95355
        • 招聘中
        • Paradigm Clinical Research -Modesto
        • 首席研究员:
          • Gopika Gangupantula, MD
      • San Diego、California、美国、92108
        • 招聘中
        • Paradigm Clinical Research Centers, LLC
        • 首席研究员:
          • Schafer Boeder, MD
    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • Barbara Davis Center for Diabetes
        • 首席研究员:
          • Halis Kaan Akturk, MD
    • Georgia
      • Atlanta、Georgia、美国、30318
        • 招聘中
        • Atlanta Diabetes Associates
        • 首席研究员:
          • Bruce W Bode, MD
    • North Carolina
      • Chapel Hill、North Carolina、美国、27514
        • 招聘中
        • UNC Eastowne Medical Office Building
        • 首席研究员:
          • Klara Klein, MD, PhD
    • Texas
      • Austin、Texas、美国、78731
        • 招聘中
        • Texas Diabetes & Endocrinology, P.A.
        • 首席研究员:
          • Thomas Blevins, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Participants >= 18 years of age
  • Fasting C-peptide levels <0.6 ng/ml
  • Average TIR < 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
  • Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
  • Willing to wear a study provided CGM for study duration
  • Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN

Key Exclusion Criteria:

  • Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
  • Have been hospitalized for DKA within 3 months
  • Have uncontrolled hypothyroidism or hyperthyroidism
  • Have QTcF interval > 450 msec for males or > 470 msec for females
  • Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
  • Have persistent, uncontrolled hypertension
  • Have clinically significant cardiovascular or cerebrovascular disease
  • Have proliferative retinopathy or maculopathy requiring acute treatment
  • Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
  • Have been diagnosed and/or treated for malignancy within 3 years
  • Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Cadisegliatin 800 mg QD, then Placebo

If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment

Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin

其他名称:
  • TTP399

Placebo (insulin alone)

实验性的:Placebo, then Cadisegliatin 800 mg QD

If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment

Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin

其他名称:
  • TTP399

Placebo (insulin alone)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To assess the change in Time in Range (TIR)
大体时间:last 2 weeks of the two 6-week treatment periods

Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

last 2 weeks of the two 6-week treatment periods

次要结果测量

结果测量
措施说明
大体时间
CGM-based metric for glycemic control
大体时间:last 2 weeks of each treatment period

Time In Tight Range (TITR)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
大体时间:last 2 weeks of each treatment period

Time Above Range (TAR)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
大体时间:last 2 weeks of each treatment period

Time Below Range (TBR)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
大体时间:last 2 weeks of each treatment period

Glucose Management Indicator (GMI)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
大体时间:last 2 weeks of each treatment period

Glucose variability (GV)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
大体时间:last 2 weeks of each treatment period

Time in Range (TIR) > 70%

last 2 weeks of each treatment period
Change in glucose control after standardized mixed meal tolerance test (MMTT)
大体时间:12 weeks

Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT)

12 weeks
Change in glucose control after standardized mixed meal tolerance test (MMTT)
大体时间:12 weeks

Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT)

12 weeks
To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence
大体时间:12 weeks

Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

12 weeks
Assess incidence of Serious Adverse Events (SAEs)
大体时间:14 weeks

Number of Serious Adverse Events (SAEs)

14 weeks
Assess incidence of Treatment Emergent Adverse Events (TEAEs)
大体时间:14 weeks

Number of treatment emergent adverse events (TEAEs)

14 weeks
Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation
大体时间:14 weeks

Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug

14 weeks
Assess incidence of Adverse Events of Special Interest (AESIs)
大体时间:14 weeks

Number of adverse events of special interest (AESIs)

14 weeks
Change from baseline in average daily total insulin dose
大体时间:last week of the two 6-week treatment periods

Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

last week of the two 6-week treatment periods

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Maria Alba, MD、vTv Therapeutics LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月29日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2026年5月15日

首先提交符合 QC 标准的

2026年5月22日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅